FDA DEVICE FACTS
Annalise Enterprise
Harrison-AI Medical Pty, Ltd.
FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。
Indications for use
Intended context: Annalise Enterprise is a device designed to be used in the medical care environment to aid in triage and prioritization of studies with features suggestive of the following findings:
- acute infarct* **See Additional Information, next page. The device analyzes studies using an artificial intelligence algorithm to identify findings. It makes study-level output available to an order and imaging management system for worklist prioritization or triage. The device is not intended to direct attention to specific portions of an image and only provides notification for suspected findings. Its results are not intended:
- to be used on a standalone basis for clinical decision making
- to rule out specific findings, or otherwise preclude clinical assessment of non-contrast computed tomography brain Intended modality: Annalise Enterprise identifies suspected findings in non-contrast brain CT studies. Intended user: The device is intended to be used by trained clinicians who are qualified to interpret CTB studies as part of their scope of practice. Intended patient population: The intended population is patients who are 22 years or older. Additional information: The device includes acute infarct of the cerebral hemispheres or cerebellum, also including early signs of acute middle cerebral artery (MCA) infarct such as insular ribbon sign and disappearing basal ganglia sign. The infarct must be a completed infarct (i.e. include an ischemic core of ≥5mL). The device also includes hyperdense artery in the anterior circulation but does not include lacunar infarcts, brainstem infarcts or venous infarcts. The radiological device definition of acute infarct includes the following territories and regions:
- anterior cerebral artery (ACA)
- middle cerebral artery (MCA)
- posterior cerebral artery (PCA)
- cerebellum
- basilar artery occlusions
- watershed regions Specificity may be reduced in the presence of infarcts of <5mL. Caution: All patients should get adequate care for their symptoms, including advanced imaging (e.g., CTA, CTP, MRI, etc.) and/or other appropriate care per standard clinical practice, irrespective of the device output. The device is not intended to be a rule-out device and for cases that have been processed by the device, an absence of a notification for suspected acute infarct should not be viewed as indicating that acute infarct is excluded. Limitations: The device does not replace the need for advanced imaging in the stroke workup. It provides workflow prioritization and notification only. Prescription Use.
Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。
OFFICIAL FDA SOURCES
FDA Record and Public Document Status
Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。